S&P 500
6,005.88
+0.1%
+$5.52
DJI
42,761.76
-0.0%
-$1.11
NASDAQ
19,591.24
+0.3%
+$61.28
Bitcoin
109,358.00
+3.7%
+3,854.85
AAPL
$201.70
-1.1%
-$2.22
AMZN
$217.31
+1.8%
+$3.74
GOOG
$177.80
+1.8%
+$3.09
META
$694.90
-0.4%
-$2.81
MSFT
$472.66
+0.5%
+$2.28
NVDA
$142.74
+0.7%
+$1.02
TSLA
$308.41
+4.5%
+$13.27
Ikena Oncology (NASDAQ: IKNA)
$1.47
(3.5%)
$0.05
Price as of June 9, 2025, 4:00 p.m. ET
Ikena Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ikena Oncology Company Info
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed, and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.